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Abstract 
Through the recent conduct of the ToGA trial, HER2 has shown to be predictive for the 
treatment with trastuzumab in advanced gastric and gastro-oesophageal cancer. When it 
comes to the prognostic properties the situation is different. Despite the fact that it is more 
than 20 years ago since the first studies demonstrating an association between a positive 
HER2 status and poor prognosis were published the issue is still controversial. In this current 
systematic review a large number of studies on HER2 and gastric cancer have been reviewed. 
The studies included in this review should fulfill the following two criteria. First criterion: The 
number of patients in each study should be ≥ 100, and the HER2 status should have been 
determined either by immunohistochemistry (IHC) or in situ hybridization (ISH). Second 
criterion: The selected articles should include an analysis of the association between the HER2 
status and survival or relevant clinicopathological characteristics. Forty-two publications with 
a total of 12,749 patients fulfilled the two criteria and were reviewed in detail. The majority of 
the publications (71%) showed that a HER2-postive status measured either by IHC or ISH was 
associated with poor survival and/or clinicopathological characteristics, such as serosal inva-
sion, lymph node metastases, disease stage, or distant metastases. Based on the current 
analysis a clear trend towards a potential role for HER2 as a negative prognostics factor in 
gastric cancer was shown, suggesting that HER2 overexpression and/or amplification is a 
molecular abnormality that might be linked to the development of gastric cancer. 
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Introduction 
HER2 has shown to possess predictive proper-
ties for the treatment with the monoclonal antibody 
trastuzumab (Herceptin, Roche/Genentech) in breast 
cancer, and the recent ToGA trial has shown similar 
characteristic in gastric cancer [1-3]. However, when it 
comes to the prognostic properties of the HER2 status 
there  seems  to  be  differences  in  how  the  marker  is 
perceived in the two diseases. For breast cancer HER2 
was  found  to  be  a  negative  prognostic  factor  very 
early on [4], but for gastric cancer there still seems to 
be no consensus, despite the fact that the first studies 
demonstrating  an  association  between  a  positive 
HER2 status and poor prognosis appeared already 20 
years ago [5, 6]. 
The gene for the HER2 protein (also known as 
ErbB-2,  c-erbB2  or  Her2/neu)  is  a  proto-oncogene 
located on the chromosome 17. The HER2 gene en-
codes a 185-kDa transmembrane tyrosine kinase re-
ceptor protein, which is a member of the HER-family 
(HER1-4) [1, 7]. HER2 amplification and overexpres-
sion have been found to promote tumorigenesis and 
to  be  involved  in  pathogenesis  of  several  human 
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cancers [1, 3]. Slamon et al. demonstrated that ampli-
fication of the HER2 gene in patients with breast can-
cer negatively impacted the recurrence of the disease 
and the survival [4]. For both gene amplification and 
overexpression  of  the  protein  similar  results  have 
subsequently been shown in a large number of stud-
ies. A recent meta-analysis, based on data from 39,730 
patients, has further confirmed the prognostic prop-
erties of a positive HER2 status in women with breast 
cancer [1]. 
For gastric or gastro-oesophageal junction cancer 
the prognostic significance of the HER2 status seems 
less clear and it has recently been discussed in relation 
to the publication of the results from the ToGA trial 
[2]. In this study the patients with HER2 positive dis-
ease  were  randomized  to  receive  chemotherapy 
(capecitabine (Xeloda, Roche) plus cispaltin or fluor-
ouracil  plus  cisplatin)  or  chemotherapy  plus 
trastuzumab.  The  primary  analysis  of  the  study 
showed a median overall survival (OS) of 13.8 month 
for the group of patients that received the combined 
treatment  of  chemotherapy  and  trastuzumab  com-
pared to 11.1 month for the group that was assigned 
to chemotherapy alone. In the discussion section of 
the  paper  recently  published  in  the  Lancet  it  was 
mentioned that the OS of 11.1 month in the group of 
patients  receiving  chemotherapy  alone  was  longer 
than  expected.  As  a  possible  explanation  for  this  it 
was stated that HER2 overexpression might already 
be conferring a better prognosis across the groups of 
patients studied. However, it was also mentioned that 
HER2 overexpression leading to a better prognosis is 
in contrast to recent studies that have showed an as-
sociation  between  HER2-positive  tumors  and  poor 
outcome and aggressive disease. The authors further 
concluded  that  more  studies  are  needed  to  address 
the issue of whether HER2 has an effect on prognosis 
in  gastric  cancer,  and  whether  it  confers  a  good  or 
poor prognosis [2].  
For more than 20 years a relatively large number 
of studies on HER2 in gastric cancer have been pub-
lished, and many of these have looked at the associa-
tion  between  a  HER2-postive  status  and  survival 
and/or important clinicopathological characteristics. 
In this current systematic review we have utilized the 
already existing literature to address the issue on the 
prognostic  properties  of  a  HER2-postive  status  in 
gastric cancer.  
Methods  
A  PubMed  search  was  undertaken  to  identify 
articles in English, from 1986 to August 2011, using 
the  key  word  “gastric  cancer”  combined  with 
“HER2”, “ErbB-2”, “c-erbB2”, and “Her2/neu”. Ad-
ditional articles were found by a manual search for 
references  from  the  already  identified  articles.  The 
articles were included in the analysis, if they fulfilled 
the following two criteria. Criterion 1: The number of 
patients studied should be ≥ 100 and the HER2 status 
should have been determined by immunohistochem-
istry (IHC) or in situ hybridization (ISH) such as flu-
orescence in situ hybridization (FISH) or chromogenic 
in situ hybridization (CISH). Criterion 2: The selected 
articles should include an analysis of the association 
between the HER2 status and survival, e.g. OS and/or 
disease-free  survival  (DFS)  and/or  relevant  clinico-
pathological characteristics such as serosal invasion, 
vascular invasion, lymph node involvement, distant 
metastases, disease stage, etc. Examples of the stain-
ing methods related to Criterion 1 are shown in Figure 
1. 
The identified articles were scored according to 
the strength of the association between the positive 
HER2 status and the prognostic information reported, 
using a three point categorical scale. If a statistic sig-
nificant association between the HER2-positive status 
and survival was reported, the studies were marked 
with two pluses (++) indicating the strongest associa-
tion. For the studies where a statistic significant asso-
ciation between the HER2-postive status and relevant 
clinicopathological  characteristics  was  found,  the 
study  was  marked  with  one  plus  (+)  indicating  a 
somewhat  weaker  association.  The  studies  were 
marked with a minus (–) where no association with a 
HER2-positive status was found. Separate tables were 
made  for  IHC  or  ISH  and  a  weighted  mean  of  the 
HER2-positive status was calculated together with the 
95% confidence interval (CI) for each of the two assay 
type. 
Results 
For the studies conducted with IHC, 48 articles 
comprising  17,338  patients  that  fulfilled  selection 
Criterion 1 were identified, and among these 38 arti-
cles comprising 11,860 patients also fulfilled Criterion 
2. The weighted  mean  HER2-positive status for the 
articles that fulfilled both selection criteria was 17.9% 
(95% CI; 14.8 to 20.9). The corresponding range for the 
HER2-positive status was  from 4.4% to 53.4%. Two 
out  of  the  38  articles  comprised  patients  both  with 
gastroesophageal  junction  and  gastric  cancer  [8,  9], 
and for the patients in the remaining articles the can-
cer  was  localized  to  the  stomach.  The  individual 
studies  and  the  association  between  HER2  overex-
pression and survival and/or relevant clinicopatho-
logical characteristics are listed in Table 1 scored ac-
cording to the 3 point categorical scale as described 
above. The article by H Grabsch et al. [10] included  Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
139 
two distinct populations, one from Germany and one 
from the UK, and these two populations have been 
treated separately and appear as two studies in Table 
1. 
In 15 of the 39 studies (39%) an association was 
found between a positive HER2 status and poor sur-
vival  (++),  and  a  similar  association  with  clinico-
pathological characteristics (+) was found in an addi-
tional 13 studies (33%). In the remaining 11 studies 
(28%)  no  association  could  be  detected  between  a 
positive HER2 status and  neither poor survival nor 
clinicopathological characteristics (−). In total for the 
IHC articles, 28 out of the 39 studies (72%) showed an 
association between a positive HER2 status and poor 
survival or clinicopathological characteristics. In the 
individual studies the analysis of the association be-
tween HER2 status and survival or clinicopathological 
characteristics were performed using both univariate 
and multivariate statistics. Twenty of the 39 studies 
used both univariate and multivariate statistics and 
for the remaining 19 studies only univariate statistics 
was  used.  For  the  studies  where  an  association  be-
tween  HER2  status  and  survival  was  demonstrated 
(++), 11 of the 15 studies in this category used multi-
variate statistics.  
For  the  studies  categorized  as  (+)  or  (++)  the 
clinicopathological characteristics that was most often 
found to be associated with a positive HER2 status 
was lymph node status, serosal invasion or the depth 
of  invasion,  disease  stage,  and  distant  metastases. 
Further, for all the IHC studies (-/+/++) an associa-
tion between overexpression of HER2 and the intes-
tinal tumor type was found in more than half of these 
studies. When the studies where the positive HER2 
status showed no prognostic value (−) were compared 
with the studies where the positive status correlated 
with poor survival or clinicopathological characteris-
tics (++ /+) there was a trend towards a lower HER2 
positivity  rate  for  the  “negative”  studies.  The 
weighted mean for the “negative” studies was 15.4% 
(95% CI; 9.4 to 19.2) compared to 18.2% (95% CI; 14.5 
to 22.0) for the positive studies, however, as shown 
the difference was not statistically significant.  
For the studies that included ISH testing, 12 ar-
ticles comprising 5,490 patients that fulfilled selection 
Criterion 1 were indentified, and among these 8 arti-
cles comprising 1,597 patients also fulfilled Criterion 
2.  The  weighted  mean  for  the  HER2-positive status 
(amplification) for the articles that fulfilled both se-
lection criteria was 12.2% (95% CI; 9.5 to 14.8). The 
corresponding range for the HER2-positive status was 
from 8.7% to 18.1%. Two out of the 8 articles com-
prised patients with both  gastroesophageal junction 
and gastric cancer [9, 13], and for the patients in the 
remaining  articles  the  cancer  was  localized  to  the 
stomach. The individual studies and the association 
between  HER2  amplification  and  survival  and/or 
relevant  clinicopathological  characteristics  are  listed 
in Table 2 scored according with the 3 point categori-
cal scale. In 5 of the listed studies [9, 11, 12, 18, 24] the 
HER2 status was determined by both IHC and ISH, 
and these articles are thus listed in Table 1 as well as 
in Table 2. 
 
Figure 1. Examples of positive HER2 status in gastric adenocar-
cinoma of the stomach with overexpression of the HER2 protein 
(IHC3+) or amplification of the HER2 gene (HER2/CEN-17 ≥ 2.0). 
A. Immunohistochemistry (HercepTest™, Dako (20×)). B. Fluo-
rescence in situ hybridization (HER2 FISH pharmDx™ Kit, Dako 
(40×)).  C.  Chromogenic  in  situ  hybridization  (HER2  CISH 
pharmDx™ Kit, Dako (40×)).  Journal of Cancer 2012, 3 
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Table 1. The individual IHC studies fulfilling both Criteria 1 and 2. 
No.  Study  Country  N  HER2+ %  Prognostic Info.  
1  Y Yonemura et al. (1991) [5]  Japan   260  11.9  ++ 
2  J K Roh et al (1992) [6]   Korea  109  31.0  ++ 
3  M Tateishi et al. (1992) [31]   Japan  179  12.0  − 
4  Y Yonemura et al. (1992) [32]   Japan  220  10.0  + 
5  T Mizutani et al. (1993) [33]   Japan  226  14.0  ++ 
6  T Ohguri et al. (1993) [34]   Japan  186  30.6  − 
7  S Uchino et al. (1993) [35]   Japan   108  11.0  ++ 
8  J-P Kim et al. (1994) [36]   Korea  152  9.2  − 
9  K Motojima et al. (1994) [37]   Japan  120  28.0  ++ 
10  S Chariyalertsak et al. (1994) [38]  Thailand  309  11.7  + 
11  A Webb et al. (1996) [39]   UK  160  8.0  + 
12  H R Lee et al. (1996) [40]   Korea  225  27.4  + 
13  C-T Shun et al. (1997) [16]   Taiwan  112  30.3  ++ 
14  M-S Wu et al. (1997) [17]   Taiwan  163  26.4  + 
15  T Ishikawa et al. (1997) [18]   Japan  375  10.4  + 
16  Y Yonemura et al. (1998) [19]   Japan  299  13.7  ++ 
17  M Nakajima et al. (1999) [20]   Japan  128  16.4  ++ 
18  J Sanz-Ortega et al. (2000) [41]   Spain  143  26.6  + 
19  A Ougolkov et al. (2000) [42]   Japan  116  12.1  − 
20  H Allgayer et al. (2000) [43]   Germany  189  53.4  ++ 
21  A Ghaderi et al. (2002) [44]   Iran   146  16.4  + 
22  T Takehana et al. (2002) [45]   Japan  352  8.2  + 
23  J Pinto-de-Sousa et al (2002) [46]  Portugal  157  15.3  ++ 
24  Y-L Wang et al. (2002) [47]   Taiwan  100  32.0  + 
25  KE Lee et al. (2003) [21]   Korea  841  16.9  − 
26  HS Song et al. (2003) [48]   Korea  739  26.2  − 
27  Z Tang et al. (2004) [49]   China  200  5.5  − 
28  DI Park et al. (2006) [22]   Korea  182  15.9  ++ 
29  AH Marx et al.(2009) [11]   Germany   166  19.0  − 
30  XL Zhang et al. (2009) [23]   China  102  18.6  ++ 
31  GZ Yu et al. (2009) [50]   China  1143  28.0  + 
32  H Grabsch et al. (2010)* [10]   Germany  418  8.6  − 
33  H Grabsch et al. (2010)* [10]   UK  506  4.4  − 
34  B Yan et al. (2010) [24]   Singapore  128  9.4  ++ 
35  S-Y Yan et al. (2011) [12]   China  145  15.2  + 
36  KC Kim et al. (2011) [25]   Korea  2009  13.8  ++ 
37  S-A Im et al (2011) [8]   Korea  142  15.7  + 
38  PL Kunz et al. (2011) [9]   USA  169  13.0  − 
39  Y-Y Wang et al. (2011) [26]   China  436  20.6  ++ 
*This article comprises both a German and an English study population. 
Symbols:  
++:  HER2 overexpression is associated with poor survival (e.g. OS, DFS, PFS, etc.) 
 +:  HER2 overexpression is associated with clinicopathological characteristics (e.g. lymph node status, serosal invasion, disease stage, 
etc.)  
 –:  No association found between HER2 overexpression and clinicopathological characteristics or poor survival. 
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Table 2. The individual ISH studies fulfilling both Criteria 1 and 2. 
No.  Study  Country  Assay  N  HER2 + %   Prognostic Info. 
1  T Ishikawa et al. (1997) [18]   Japan  FISH  105  18.1  + 
2  M Tanner et al. (2005) [13]   Finland  CISH  231  17.3  ++ 
3  AH Marx et al.(2009) [11]   Germany   FISH  166  16.0  – 
4  JD Barros-Silva et al. (2009) [27]   Portugal  FISH  463   9.3  ++ 
5  B Yan et al. (2010) [24]   Singapore  FISH/CISH  128  11.7  ++ 
6  C B Moelans et al. (2011) [28]   Netherlands/Poland/ 
Finland/USA 
CISH  195  8.7  – 
7  S-Y Yan et al. (2011) [12]   China  FISH  145  12.4  + 
8  PL Kunz et al. (2011) [9]   USA  FISH  164  9.5  – 
Symbols:  
++:  HER2 amplification is associated with poor survival (e.g. OS , DFS, PFS, etc.) 
 +:  HER2 amplification is associated with clinicopathological characteristics (e.g. lymph node status, serosal invasion, disease stage, etc.)  
 –:  No association found between HER2 amplification and clinicopathological characteristics or poor survival. 
 
 
In 3 of the 8 studies (37.5%) an association was 
found between a positive HER2 status and poor sur-
vival (++) and in further 2 studies (25%) a similar as-
sociation was found with regards to clinicopatholog-
ical  characteristics  (+).  In  the  remaining  3  studies 
(37.5%) no association could be detected between a 
positive HER2 status and  neither poor survival nor 
clinicopathological characteristics (−). In total for the 
ISH articles, 5 out of the 8 studies (62.5%) showed an 
association between a positive HER2 status and poor 
survival or clinicopathological characteristics. For the 
individual studies the analysis of the association be-
tween HER2 status and survival or clinicopathological 
characteristics were performed using univariate sta-
tistical methods only. 
For  the  studies  categorized  as  (+)  or  (++)  the 
clinicopathological characteristics that was most often 
found to be associated with a positive HER2 status 
was  the  same  as  mentioned  for  the  IHC  studies. 
Moreover, with respect to HER2 gene amplification an 
association with the intestinal tumor type was found 
in  more  than  half  of  the  studies.  When  the  studies 
where the positive HER2 status showed no prognostic 
value (−) was compared with the studies where the 
positive status correlated with poor survival or clini-
copathological characteristics (++ /+) the HER2 posi-
tivity rate seemed to be similar. The weighted mean 
for the “negative” studies was 13.3% (95% CI; 6.7 to 
15.8), and the corresponding value for the “positive” 
studies was 12.6% (95% CI; 9.3 to 15.9).  
If the IHC studies in Table 1 are pooled with the 
ISH studies in Table 2 the total number increases to 
42, comprising altogether 12,479 patients. The 5 stud-
ies [9, 11, 12, 18, 24], where the HER2 status was de-
termined by both IHC and ISH are only counted once. 
In 17 of these 42 studies (~ 40%) an association be-
tween a positive HER2 status and poor survival (++) 
was found, and an additional 13 studies (~ 31%) sim-
ilarly showed a relationship with clinicopathological 
characteristics  (+).  In  the  last  12  studies  (~29%)  no 
association between a positive HER2 status and poor 
survival or clinicopathological characteristics could be 
detected  (−).  Overall,  this  means  that  in  30  studies 
(71%) an association between a positive HER2 status 
and poor survival and/or relevant clinicopathological 
characteristics could be found. Figure 2 illustrates the 
number of IHC and ISH studies and patients in each 
of the three scoring categories. 
 
 
Figure 2. The number of IHC and ISH studies and patients (N) in 
each of the three scoring categories. Symbols: Two pluses (++) 
indicate the strongest association with the HER2+ status, one plus 
(+)  indicates  a  somewhat  weaker  association  with  the HER2+ 
status,  and  minus  (–)  indicates  that  no  associations  with  the 
HER2+ was found.  Journal of Cancer 2012, 3 
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Discussion 
This  systematic  review  has  been  based  on  42 
publications covering the period from 1991 to August 
2011  and  comprises  a  total  of  12,749  patients  with 
gastric cancer. The majority of the articles (71%) re-
viewed showed that a HER2-postive status measured 
either by IHC or ISH provides additional prognostic 
information either related to survival (40%) or to rel-
evant clinicopathological characteristics (31%), which 
included already established prognostic factors such 
as serosal invasion and lymph node metastases [14]. A 
clear  trend  towards  a  potential  role  for  HER2  as  a 
negative  prognostic  factor  in  gastric  cancer  was 
shown,  although  the  data  is  not  as  consistent  com-
pared to what has been reported for breast cancer [1]. 
An issue that weakens the conclusion in this system-
atic review is the fact that multivariate statistics was 
only used in approximately half of the reported stud-
ies.  However,  it  has  recently  been  suggested  that 
HER2  overexpression  and/or  amplification  may  be 
one of the molecular abnormalities linked to the de-
velopment of gastric cancer, especially in the intesti-
nal  phenotype  [15],  and  this  support  the  data  pre-
sented in this review. For the studies in the current 
review that have looked at the Lauren classification in 
relation to HER2, a higher level of overexpression or 
amplification was found in the intestinal phenotype 
compared to the diffuse or mixed types [8-12, 16-21, 
23, 25, 27, 28, 41, 44, 46-48]. A few of the IHC studies 
also seems to show that the expression of HER2 in-
creased with disease progression [5, 33, 34, 38].  
Based  on  the  results  of  the  current  review  it 
seems  unlikely  that  HER2  overexpression  or  HER2 
gene amplification could act as a positive prognostic 
factor in gastric cancer, as has been hypothesized in 
the  publication  of  the  ToGA  trial  in  the  Lancet  [2]. 
None of the articles that fulfilled Criteria 1 and 2 in 
this  analysis  support  this  hypothesis.  Possible  con-
founding factors, such as a wider use of second line 
treatments and a possible better prognosis related to 
the  intestinal  phenotype,  should  be  taken  into  con-
sideration when interpreting the data from the ToGA 
trial [15]. With regards to the latter it is worth men-
tioning  that  approximately  75%  of  the  patients  in-
cluded in the ToGA trial had tumors of the intestinal 
type [2], which seems to be high compared to most of 
the studies reported in this review. In support of the 
hypothesis put forward in the Lancet article one study 
has been identified, which, in fact, showed that over-
expression of the HER2 resulted in a better prognosis 
compared to those who did not overexpress the pro-
tein.  However,  this  study  was  not  included  in  this 
review  due  to  the  number  of  patients  being  <100 
(Criterion  1).  Here,  samples  from  93  patients  with 
advanced gastric carcinoma were investigated using 
IHC. Overexpression of  HER2 was found in 10 pa-
tients  (11%)  and  a  multifactorial  analysis  showed  a 
significantly  better  prognosis  for  those  patients  in 
relation to survival [29]. 
A  relatively  large  variation  was  found  in  the 
HER2 positivity rate between the individual studies 
included in this review as appears from Table 1 and 
Table 2. Here, the largest variation was seen in the 
IHC studies, where the range in relation to the per-
centage of patients with HER2 positive tumors was 
found to be between 4.4% and 53.4%. The explanation 
for this rather large variation is likely to be multifac-
torial such as the difference in the populations stud-
ied, but the most important aspects are probably the 
use of non-standardized assays using different anti-
bodies and the application of different scoring criteria 
for the stained slides. In the majority of the studies 
conducted within the last couple of years the scoring 
criteria developed by Hofmann et al. for the ToGA 
trial [30] or related were used, which seems to have 
resulted in less variation (range: 9.4% - 15.7) [8, 9, 12, 
24, 25]. Also for the ISH studies some variation in re-
lation to the percentage of patients with amplification 
of the HER2 gene (range: 8.7%-18.1 0%) was found, 
although the magnitude is much smaller. This is likely 
explained by the fact that the FISH and CISH assays 
are quantitative methods compared to IHC, which use 
a semi-quantitative scoring system.  
Despite the fact that the number of studies con-
ducted with IHC is much higher than for ISH there 
seems  to  be  no  major  differences  in  the  results  ob-
tained. For the IHC articles, 72 % of the studies (28 out 
of  the  39)  showed  an  association  between  HER2+ 
status  and  poor  survival  and/or  clinicopathological 
characteristics (++/ +). The similar figures for the ISH 
studies were 63% (5 out of the 8). The trend towards a 
lower HER2 positivity rate for the “negative” studies 
that was observed for IHC may be explained by the 
large variation seen with this type of assay compared 
to ISH as described above.  
Conclusion  
The analysis of 42 publications comprising a to-
tal of 12,749 patients with gastric cancer showed that a 
positive HER2 status, measured either by IHC or ISH, 
adds  information  to  the  prognosis  of  the  disease. 
Based on the current analysis a clear trend towards a 
potential role for HER2 as a negative prognostic factor 
in  gastric  cancer  was  shown,  which  suggests  that 
HER2 overexpression and/or amplification might be 
a molecular abnormality linked to the development of 
gastric cancer.   Journal of Cancer 2012, 3 
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